Methods of treating fulminant viral hepatitis with an IL-18 antagonist in a patient with an IL-18BP variant
AssigneeThe Rockefeller University
InventorJean-Laurent Casanova
Life of this patent
Estimating the term…
Abstract
The invention relates to mutations and alterations in the inflammatory pathway, including IL-18BP and IL-10RB mutations, that are associated with the development of fulminant viral hepatitis following viral infection, such as following hepatitis virus infection. The invention relates to methods for treating or ameliorating viral hepatitis comprising administering IL-18BP, IL-18 antagonist, IFNγ antagonist or inhibitor, and/or IL-10RB or an IL-10 antagonist.
Claims14
A method of treating or preventing fulminant viral hepatitis in a patient comprising
- administering an interleukin-18 (IL-18) antagonist comprising interleukin-18 binding protein (IL-18BP) to a patient in need thereof,
- wherein the patient comprises cells having a IL-18BP gene or protein variant wherein IL-18 binding of IL-18BP is absent or altered.
A method for evaluating and treating a patient with a liver tropic virus infection so as to alleviate, treat or prevent fulminant viral hepatitis comprising assessing the gene encoding interleukin-18 binding protein (IL-18BP) in the patient, or assessing the IL-18BP protein in the patient to determine whether IL-18BP is mutated to prevent IL-18 binding or result in loss of function of IL-18BP, the method further comprising administering to the patient an interleukin-18 (IL-18) antagonist comprising interleukin-18 binding protein (IL-18BP), whereby fulminant viral hepatitis is alleviated, treated or prevented in the patient.
Dependencies are inferred from the claim text.